Placebo-Controlled, Double-Blind, Study to Determine the Safety and Efficacy of SDX in Patients With IH

Idiopathic Hypersomnia Clinical Trial

Official title:

A Phase 2, Placebo-Controlled, Double-Blind, Randomized Withdrawal Study to Determine the Safety and Efficacy of Oral SDX in Patients With Idiopathic Hypersomnia (IH)

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT05668754
• Other study ID #: KP1077.D01
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: December 28, 2022
• Est. completion date: June 30, 2024

Study information

• Verified date: January 2024
• Source: Zevra Therapeutics
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a study of the safety, efficacy and pharmacokinetics (PK) of Serdexmethylphenidate (SDX) compared to placebo in subjects with Idiopathic Hypersomnia (IH).

Description:

SDX is a prodrug of dexmethylphenidate (d-MPH). SDX behaves as a prototypical prodrug that is devoid of pharmacological effects until metabolized to active d-MPH. Central nervous system (CNS) stimulants, including d-MPH products, are being used off-label by patients with IH. The potential advantage of SDX-derived d-MPH is its unique PK profile with rising d-MPH plasma concentrations at approximately 3 hours postdose followed by a broad peak from approximately 8 to 12 hours postdose (without sharp exposure spikes), and a gradual decline after the peak. The optimal dose of SDX will be determined for each participant by titration based on individual tolerability and response during the 5-week SDX-only Open-Label Titration period (OLTP), after which 2/3 of the participants will continue to receive SDX and 1/3 of the participants will receive placebo (withdrawal design) in the 2-week Double-Blind Withdrawal Period (DBWP). The study will evaluate safety (primary endpoint), efficacy and PK in patients with IH after daily oral administration of SDX either once per day in the evening (qd pm) or twice per day (morning and evening: bid). The study is expected to inform about the optimal SDX dose range and the best dose regimen (nighttime dosing or twice-per-day) for further studies in patients with IH and narcolepsy. The evening dosing regimen (just before bedtime) is of interest since there is little or no exposure to d-MPH for the first several hours post-dose and the mean peak d-MPH concentration occurs at 10-12 hours post-dose (ie, in the morning after a nighttime dose).

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 48
• Est. completion date: June 30, 2024
• Est. primary completion date: June 30, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. At least 18 years of age at the time of consent

2. Body Mass Index (BMI) =35 kg/m2

3. Documented primary diagnosis of IH according to the International Classification of Sleep Disorders (ICSD-3) criteria

4. At the Screening Visit and Baseline Visit (start of OLTP), Epworth Sleepiness Scale (ESS) scores =11

5. Average nightly Total Sleep Time (TST) of =7 hours, per subject history and confirmed during screening.

6. Subject must be in general good health defined as the absence of any clinically relevant abnormalities as determined by the Investigator based on physical and neurological examinations, vital signs, ECGs, medical history, and clinical laboratory values (hematology, chemistry, and urinalysis) at Screening.

7. If currently treated with nicotine replacement therapy, must have been taking the same regimen and dose for at least 2 months prior to screening and must agree to take the same dose during the study.

8. Have used a medically acceptable method of contraception for at least 2 months prior to the first dose of study drug and consent to use a medically acceptable method of contraception from the first dose of study drug, throughout the entire study period, and for 90 days after the last dose of study drug. Exclusion Criteria

1. Hypersomnia due to another medical, behavioral, or psychiatric disorder condition (eg, narcolepsy, depression disorders, multiple sclerosis, Parkinson's disease, stroke).

2. Clinically significant sleep-related breathing disorders, including sleep apnea, treatment with Continuous Positive Airway Pressure (CPAP) therapy, Obstructive Apnea Hypopnea Index (AHI) >15 episodes per hour, or hypoventilation.

3. Clinically significant parasomnias (eg, sleep walking, rapid eye movement [REM] sleep behavior disorder, etc).

4. Periodic Limb Movement Disorder (PLMD) Arousal Index (PLMA-I) >15 during Screening PSG, a historical diagnosis of PLMD (last 10 years), or a PLMD diagnosis older than 10 years with current (last 60 days) treatment or symptoms of rhythmic movements involving one or both legs during sleep.

5. Occupation requiring nighttime shift work or variable shift work with early work start times (before 6 AM), if this occurs more than once per week.

6. Planned travel during the study that includes more than 3 time zones, or planned travel that includes 3 time zones on more than 2 occasions during the study.

7. Going to sleep for the night later than 1 AM at a frequency of more than once per week.

8. Current or past (within 1 year) major depressive episode according to DSM-5 criteria.

9. Any history of attempted suicide (lifetime) or clinically significant suicidal ideation, in the opinion of the Investigator, based on the C-SSRS assessment at Screening.

10. Any clinically significant unstable medical abnormality, chronic disease (eg, asthma or diabetes), or a history of a clinically significant abnormality of the cardiovascular, central nervous system,

11. Any of the following out-of-range vital signs at Screening: systolic blood pressure outside 90-145 mmHg; diastolic blood pressure outside 50-90 mmHg; resting heart rate outside 40-100 beats per minute.

12. History or presence of abnormal ECGs, which in the Investigator's opinion is

clinically significant, including the following:

1. ECG findings of ischemia or infarct

2. Complete bundle branch blocks

3. Symptomatic arrhythmias as ventricular arrhythmias (non- sustained ventricular tachycardia (VT), multifocal or frequent premature ventricular contractions), bundle branch block, axis deviation, or abnormal or any predominantly non-sinus- conducted rhythm.

4. QTcF >450 msec for males or >470 msec for females, on Screening ECG.

5. PR interval outside the range of 120 to 220 msec on Screening ECG

13. Estimated glomerular filtration rate (GFR) at Screening <60 mL/min/1.73 m2.

14. Malignant neoplastic disease requiring therapy within 2 years prior to Screening or during the study, or clinically relevant as judged by the Investigator.

15. Uncontrolled thyroid disorder as evidenced by thyroid stimulating hormone (TSH) =0.8 x the lower limit of normal (LLN) or =1.25 x the upper limit of normal (ULN) for the reference laboratory at Screening.

16. Laboratory value for aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >3 x upper limits of normal (ULN).

17. Excessive caffeine use during the 10 days prior to first dose of study drug or anticipated excessive use defined as >600 mg/day of caffeine during the treatment periods of the study.

18. Treatment or planned treatment with prohibited medications (including medications that may affect daytime sleepiness and nighttime sleep) or unwilling to refrain from any prohibited medications. Treatment must have been discontinued 14 days or 5 half-lives, whichever is longer, prior to the first dose of study medication (and at least 30 days for sedating antidepressants; at least 14 days for CNS stimulants).

19. Current or past (within 12 months prior to Screening) substance use disorder (including alcohol and psychoactive cannabinoids) according to DSM-5 criteria; current or past history of substance abuse treatment (including alcohol), or unwilling to refrain from substance use (including alcohol) during the study.

20. Nicotine dependence that has an effect on sleep (eg, a subject who routinely awakens at night to smoke).

21. Evidence of substance or alcohol use or has a positive urine or breath alcohol or positive urine drug screen at Screening.

Related Conditions & MeSH terms

• Disorders of Excessive Somnolence
• Idiopathic Hypersomnia

Intervention

Drug:
• Serdexmethylphenidate
Participants randomized to active drug will receive their optimized dose according to a dosing regimen set by randomization at the start of the OLTP. The 4 possible oral SDX doses are 80, 160, 240, or 320 mg/day. The optimal SDX dose will be determined during the 5-week OLTP preceding the 2-week DBWP.

Other:
• Placebo
Participants randomized to placebo will receive matching placebo capsules to the optimized dose established at the end of the OLTP, according to a dosing regimen set by randomization at the start of the OLTP.

Locations

Country	Name	City	State
United States	Global Research Associates	Atlanta	Georgia
United States	Neurotrials Research, Inc	Atlanta	Georgia
United States	Futuresearch Trials Of Neurology	Austin	Texas
United States	Mid-Atlantic Epilepsy and Sleep Center - Bethesda	Bethesda	Maryland
United States	Sleep Disorders Center Of Alabama	Birmingham	Alabama
United States	Medical University Of South Carolina (MUSC) - Institute Of Psychiatry (IOP)	Charleston	South Carolina
United States	Intrepid Research	Cincinnati	Ohio
United States	Saint Francis Sleep Allergy and Lung Institute LLC	Clearwater	Florida
United States	Delta Waves, Inc.	Colorado Springs	Colorado
United States	Bogan Sleep Consultants	Columbia	South Carolina
United States	University of Missouri School Of Medicine	Columbia	Missouri
United States	Amr Daphne	Daphne	Alabama
United States	Ohio Sleep Medicine Institute	Dublin	Ohio
United States	Dfw Clinical Research Associates	Fort Worth	Texas
United States	Clinical Research of Gastonia (CRG)	Gastonia	North Carolina
United States	Lakeview Clinical Research	Guntersville	Alabama
United States	New Generation of Medical Trials	Hialeah	Florida
United States	Houston Clinical Research Associates	Houston	Texas
United States	SOCAL Clinical Research	Huntington Beach	California
United States	Western Michigan University Homer Stryker Md School of Medicine	Kalamazoo	Michigan
United States	The University of Kansas Medical Center Research Institution Inc.	Kansas City	Kansas
United States	Barrett Clinic	La Vista	Nebraska
United States	Global Medical Institutes LLC- Princeton Medical Institute	Lawrence Township	New Jersey
United States	Brian Abaluck, LLC	Malvern	Pennsylvania
United States	Angels Clinical Research	Miami	Florida
United States	Clinical Trial Services, Corp	Miami	Florida
United States	Ivetmar Medical Group	Miami	Florida
United States	Somnology Research Associates	Miami	Florida
United States	Neurocare, Inc.	Newton	Massachusetts
United States	Henry Ford Health - Columbus	Novi	Michigan
United States	Thomas Jefferson University	Philadelphia	Pennsylvania
United States	Stanford University	Redwood City	California
United States	Clayton Sleep Institute, Llc	Saint Louis	Missouri
United States	Pasadena Center for Medical Research	Saint Petersburg	Florida
United States	Sleep Therapy & Research Center	San Antonio	Texas
United States	Sleep Medicine Specialists of California	San Ramon	California
United States	SDS Clinical Trials, Inc	Santa Ana	California
United States	Clinical Neurophysiology Services PC	Sterling Heights	Michigan
United States	Clinical Research Institute - Stockbridge	Stockbridge	Georgia
United States	TPMG Clinical Research - Williamsburg	Williamsburg	Virginia
United States	Clinical Site Partners, LLC - Winter Park	Winter Park	Florida

Sponsors (2)

Lead Sponsor	Collaborator
Zevra Therapeutics	Rho, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety parameters - TEAEs	Type and frequency of Treatment-Emergent Adverse Events	Time Frame: Start of OLTP to end of DBWP (7 weeks)
Primary	Safety parameter - Heart Rate	Change from baseline in heart rate (beats/minute).	Time Frame: Start of OLTP to end of DBWP (7 weeks)
Primary	Safety parameter - Blood Pressure	Change from baseline in blood pressure (mmHg).	Time Frame: Start of OLTP to end of DBWP (7 weeks)
Primary	Safety parameter - Laboratory Tests	Clinical significant change from baseline in clinical laboratory tests.	Time Frame: Start of OLTP to end of DBWP (7 weeks)
Primary	Safety parameter - ECG	Clinical significant change from baseline in electrocardiogram (ECG).	Time Frame: Start of OLTP to end of DBWP (7 weeks)
Primary	Safety parameter - PSQI	Change from baseline in Pittsburg Sleep Quality Index Question #6. Sleep quality score ranging from very good (0) to very bad (4).	Time Frame: Start of OLTP to end of DBWP (7 weeks)
Secondary	Change from baseline in Epworth Sleepiness Scale (ESS) score	Scores level of daytime sleepiness ranging from 0 to 24, with a higher score indicating worsened sleepiness	Start to end of DBWP (2 weeks)
Secondary	Change from baseline in Brain Fog score	Queries for frequency, severity, and symptoms of cognitive impairment in the last week.	Time Frame: Start to end of DBWP (2 weeks)
Secondary	Percentage of participants with increase (worsening) of 2 points or more from baseline in the Clinical Global Impression of Severity (CGI-S)	Clinician-reported level of illness.	Start to end of DBWP (2 weeks)
Secondary	Percentage of participants with increase (worsening) of 2 points or more baseline in the Patient Global Impression of Severity (PGI-S).	Patient-reported level of illness.	Start to end of DBWP (2 weeks)
Secondary	Change from baseline in Total Score of the Idiopathic Hypersomnia Severity Hypersomnia Scale (IHSS)	Patient-reported questionnaire assessing the severity of excessive sleepiness, prolonged sleep duration, cognitive impairment and sleep inertia. The total score ranges from 0 to 50, with higher scores indicating more severe symptoms.	Start to end of DBWP (2 weeks)
Secondary	Change from baseline in Modified Karolinska Sleepiness Scale in the morning and late afternoon.	Patient-reported at-the-moment sleepiness, ranging from 1 (extremely alert) to 10 (extremely sleepy, can't keep awake).	Start to end of DBWP (2 weeks)
Secondary	Change from baseline in Patient-Reported Outcomes Measurement Information System-29 (PROMIS-29) total scores for depression, fatigue, and social functioning.	Queries functioning and well-being in the last week.	Start to end of DBWP (2 weeks)
Secondary	Change from baseline in the Patient-Reported Wakefulness Questionnaire (ZOGIM-A) total scores.	Queries alertness over the course of the day.	Start to end of DBWP (2 weeks)
Secondary	Change from baseline in the Sleep Inertia Visual Analog Scale (SIVAS) score.	Patient-reported measure of the difficulty of waking up in the morning, ranging from 0 (very easy) to 100 (very difficult)	Start to end of DBWP (2 weeks)